Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania

Cancer

Volumn 100, Issue 12, 2004, Pages 2512-2532

  Schwartz, Gordon F ^a   Hortobagyi, Gabriel N ^b   Cady, Blake ^c   Clough, Krishna B ^d   D'Ugo, Domenico M ^e   Esserman, Laura J ^f   Fentiman, Ian S ^g   Gentilini, Oreste ^h   Giuliano, Armando E ⁱ   Mamounas, Terry P ^j   Pressman, Peter I ^k   Rutgers, Emiel J Th ^l   Terribile, Daniela ^e   Tsangaris, Theodore N ^m   Untch, Michael ⁿ   Van De Velde, Cornelis J H ^o   Buzdar, Aman U ^b   Hayes, Daniel F ^p   Hudis, Clifford ^q   Rixe, Olivier ^r   Smith, Edward ^s   Swain, Sandra M ^t   Buchholz, Thomas A ^b   Komarnicky, Lydia T ^u   Kuske, Robert R ^v   McCormick, Beryl ^q   Solin, Lawrence J ^w   Gorstein, Fred ^a   Holland, Roland ^x   Masood, Shahla ^y   Page, David L ^z   Palazzo, Juan P ^a   Brenner, R James ⁱ   Feig, Stephen A ^aa   Kopans, Daniel B ^ab   more..

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d INSTITUT CURIE   (France)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GUY S HOSPITAL   (United Kingdom)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ JOHN WAYNE CANCER INSTITUTE   (United States)

^j Aultman Center Center   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m JOHNS HOPKINS HOSPITAL   (United States)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^s INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^t NATIONAL CANCER INSTITUTE   (United States)

^u DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^v Arizona Oncology Services   (United States)

^w UNIVERSITY OF PENNSYLVANIA   (United States)

^x RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^y UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^z VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^aa MOUNT SINAI MEDICAL CENTER   (United States)

^ab MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONFERENCE PAPER; CONSENSUS; EARLY DIAGNOSIS; HUMAN; INCIDENCE; INFLAMMATION; LONG TERM CARE; MASTECTOMY; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL; TREATMENT INDICATION;

EID: 2642517065     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20298     Document Type: Conference Paper

References (137)

1. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-169.
2. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. [review] Lancet. 2002;359:909-919.
3. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
5. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348:1189-1196.
6. Fisher B, Carbone P, Economou SG, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975;292:117-122.
7. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405-410.
8. Buzdar AU, Blumenschein GR, Krutchik AN, et al. Combined modality approach for inflammatory breast cancer: prolongation of disease-free interval and survival. Cancer Bull. 1979;31:95.
9. Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983;51:763-768.
10. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1:53-59.
11. Haagensen CD, Stout AP. Carcinoma of the breast. Criteria of inoperability. Am Surg. 1943;118:859-866.
12. Haagensen CD, Stout AP. Carcinoma of the breast. Criteria of inoperability. Am Surg 1943;118:1032-1040.
13. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview [review]. Drugs. 1997;54(Suppl 4):1-7.
14. Hortobagyi GN, Buzdar AU. Locally advanced breast cancer: a review including the M.D. Anderson experience. In: Ragaz J, Ariel IM, editors. High-risk breast cancer. 1st edition. Berlin: Springer-Verlag, 1991:382-415.
15. Jacquillat C, Weil M, Auclerc G, et al. Neo-adjuvant chemotherapy in the conservative management of breast cancers - study on 205 patients. In: Jacquillat C, Weil M, Khayat D, editors. Neo-adjuvant chemotherapy. 1st edition. London: John Libbey, 1986:197-206.
16. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990;66(1):119-129.
17. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539-1545.
18. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62:2507-2516.
19. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer. 1981;47:170-175.
20. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305:6-11.
21. Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer. 1983;51:1941-1943.
22. Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 1977;39(Suppl):2827-2839.
23. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665-673.
24. De La Garza JG, De La Huerta R, Torres R, Sanchez C. Different management of inflammatory breast carcinoma (chemo-RX-chemo)-experience in 18 cases during a 6 years period (1970-1976) [abstract C-32]. Proc Am Assoc Cancer Res. 197718:274.
25. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93-100.
26. Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer [review]. C Cancer J Clin. 1995;45:227-243.
27. Schwartz GF, Cantor RI, Biermann WA. Neoadjuvant chemotherapy before definitive treatment for Stage III carcinoma of the breast. Arch Surg. 1987;122:1430-1434.
28. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994;73:362-369.
29. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-2493.
30. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
31. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502-508.
32. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46: 2578-2581.
33. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
34. Skipper HE, Schabel FMJ, Mellett LB, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431-450.
35. Skipper HE. Adjuvant chemotherapy. Cancer. 1978;41:936-940.
36. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treatment Rep. 1976;60:1749-1760.
37. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer [review]. Cancer. 1977;40(Suppl):574-587.
38. Gundoz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39:3861-3865.
39. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-1466.
40. NSABP. The effect of primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results of NSABP Protocol B-27 [abstract 5]. Breast Cancer Res Treat. 2001;69(3):210.
41. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer. 1993;29A:1843-1848.
42. Makris A, Powles TJ, Allred DC, et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat. 1998;48:11-20.
43. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999;17:3058-3063.
44. Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9:33-41.
45. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-4237.
46. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72-78.
47. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20:1304-1310.
48. Frye D, Buzdar A, Hortobagyi G. Prognostic significance of axillary nodal involvement after preoperative chemotherapy in stage III breast cancer [meeting abstract]. Proc Am Soc Clin Oncol. 1995;14:A81.
49. Singletary SE, Allred C, Ashley P, et al. Breast. In: Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging handbook, 6th edition. New York: Springer-Verlag, 2002: 257-281.
50. Haagensen CD. A technique for radical mastectomy. Surgery. 1946;19:100-131.
51. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 1992;69:2849-2852.
52. Lesnick G, Perloff M, Korzun A, Chu F, Norton L, Holland J. Combination chemotherapy prior to surgery or radiotherapy in locally advanced breast cancer. In: Jacquillat C, Weil M, Khayat D, editors. Neo-Adjuvant chemotherapy. 1st edition. Paris: Libbey, 1986:207-211.
53. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987;47 3889-3894.
54. Cocconi G, di Blasio B, Bisagni G, Alberti G, Botti E, Anghinoni E. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol. 1990;13:226-232.
55. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambetti M, Ferrari L. Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy [review]. Semin Oncol. 1991;18:515-524.
56. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer [corrected and republished article originally printed in Eur J Cancer. 1993;29A(4):592-595]. Eur J Cancer. 1993;29A:1796-1799.
57. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer [corrected and republished article originally printed in Eur J Cancer. 1993;29A(4):592-595]. Eur J Cancer. 1993;29A:1796-1799.
58. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995;13:424-429.
59. Veronesi U. NIH consensus meeting on early breast cancer [review]. Eur J Cancer. 1990;26:843-844.
60. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
61. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer [review]. J Clin Oncol. 2001;19:3817-3827.
62. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative doxetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from NSABP Protocol B-27. J Clin Oncol. 2003;24:4165-4174.
63. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999;17:855-861.
64. Burn I. The present role of adrenalectomy in breast cancer. Semin Surg Oncol. 1985;1:132-138.
65. Anderson EDC, Forrest APM, Levack PA, Chetty U, Hawkins RA. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer. 1989;60:223-226.
66. Cheung KL, Howell A, Robertson JF. Preoperative endocrine therapy for breast cancer [review]. Endocr-Relat Cancer. 2000;7:131-141.
67. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 2000;6:2229-2235.
68. Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66:191-199.
69. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-3816.
70. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001;7:1230-1236.
71. Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 2002;13:293-298.
72. Hoff PM, Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000;88:2054-2060.
73. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12:1527-1532.
74. Gazet JC, Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988;1:679-681.
75. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective [review]. Eur J Cancer. 2002;38:2214-2221.
76. Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blamey RW. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast. 1998;7:335-339.
77. Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer. 1992;28A: 908-910.
78. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14:2843-2877.
79. Shin HJ, Sneige N. Is a diagnosis of infiltrating versus in situ ductal carcinoma of the breast possible in fine-needle aspiration specimens? Cancer 1998;84:186-191.
80. Smith BL. Approaches to breast-cancer staging [editorial]. N Engl J Med. 2000;342:580-581.
81. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002;9:228-234.
82. Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001;182:601-608.
83. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks [review]. Cancer. 2003;98:1150-1160.
84. Edeiken BS, Fornage BD, Bedi DG, et al. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology. 1999;213:895-900.
85. Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg. 2001;181:313-318.
86. Boerner S, Fornage BD, Singletary E, Sneige N. Ultrasound-guided fine-needle aspiration (FNA) of nonpalpable breast lesions: a review of 1885 FNA cases using the National Cancer Institute-supported recommendations on the uniform approach to breast FNA. Cancer. 1999;87:19-24.
87. Fornage BD, Coan JD, David CL. Ultrasound-guided needle biopsy of the breast and other interventional procedures [review]. Radiol Clin North Am. 1992;30:167-185.
88. Merchant TE, Obertop H, de Graaf PW. Advantages of magnetic resonance imaging in breast surgery treatment planning. Breast Cancer Res Treat. 1993;25:257-264.
89. Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology. 1995;196:115-122.
90. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999;17:110-119.
91. Hylton N. Dedicated Breast MRI Systems Working Group report. J Magn Reson Imaging. 1999;10:1006-1009.
92. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002;179:1193-1199.
93. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000;83:1480-1487.
94. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J. 2002;8:97-100.
95. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9:235-242.
96. Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000;88:2540-2545.
97. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18:3480-3486.
98. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000;24:1266-1272.
99. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89:2187-2194.
100. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy [review]. Surg Clin North Am. 2003;83:931-942.
101. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 2003;9:374-379.
102. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001 [review]. Oncologist. 2001;6:376-385.
103. Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr. 2001;30:72-79.
104. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
105. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 [abstract 12]. Proc Am Soc Clin Oncol. 2003;22:4a.
106. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8:1073-1079.
107. Nabholtz JM, Pienkowski T, Mackey J, et al., and Breast Cancer International Research Group. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 Study [abstract 140]. Proc Am Soc Clin Oncol. 2003;21:36a.
108. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer-a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977;39:1289-1294.
109. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol. 2001;74:983-986.
110. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 2000;92:179-181.
111. Hortobagyi GN, Buzdar A, Holmes FA, et al. Non-cross resistant adjuvant chemotherapy in the multidisciplinary management of locally advanced breast cancer [abstract 14]. Presented in: Proceedings of the 7th International Congress on Anti-Cancer Treatment, Paris, France, February 3-6, 1997.
112. Hortobagyi G, Holmes F, Frye D, et al. Comparison of two adjuvant chemotherapy programs for locally advanced breast cancer: a prospective randomized trial [abstract 77]. Proc Am Soc Clin Oncol. 1990;9:21.
113. Buchholz TA, Hill BS, Tucker SL, et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001;7:413-420.
114. Baillet F, Rozec C, Ucla L, Chauveinc L, Housset M, Weil M. Treatment of locally advanced breast cancer without mastectomy. 5- and 10-year results of 135 tumors larger than 5 centimeters treated by external beam therapy, brachytherapy, and neoadjuvant chemotherapy. Ann N Y Acad Sci. 1993;698:264-270.
115. Thoms WW Jr., McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739-745.
116. Gianni L, Baselga J, Eiermann W, et al., and ECTO Study Group. First report of the European Cooperative Trial in Operable breast cancer (ECTO): effects of primary systemic therapy on local-regional disease [abstract 132]. Proc Annu Meet Am Soc Clin Oncol. 2002;21:34a.
117. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer [review]. Clin Cancer Res. 2003;9(1 Pt2):502S-510S.
118. Osteen RT. Selection of patients for breast conserving surgery. Cancer. 1994;74:366-371.
119. NIH Consensus Development Conference on the Treatment of Early-Stage Breast Cancer. Bethesda, Maryland, June 18-21, 1990 [review]. J Natl Cancer Inst Monogr. 1992;11:1-187.
120. Morrow M, Strom EA, Bassett LW, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52:277-300.
121. Pierce LJ, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1992;23:949-960.
122. Ring A, Smith I, Webb A, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy in early breast cancer? J Clin Oncol. 2003;21(24): 4540-4545.
123. De Lena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer. Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials. 1981;4:229-236.
124. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat. 1990;15:137-147.
125. Green MC, Hortobagyi GN. Chemotherapy for breast cancer. In: Hunt KK, Robb GL, Strom EA, Ueno NT, editors. Breast cancer. 1st edition. New York: Springer, 2001:309-341.
126. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10:47-52.
127. Schwartz GF. Breast conservation following induction chemotherapy for locally advanced breast cancer: a personal experience. Breast J. 1996;2:78-82.
128. Honkoop AH, Pinedo HM, De Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol. 1997;107:211-218.
129. Wang J, Bucholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer. 2002;94:3107-3114.
130. Buchholz TA, Strom EA, Perkins GH, et al. Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist. 2002;7:539-546.
131. Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20:17-23.
132. Bartelink H. Post-mastectomy radiotherapy: recommended standards [review]. Ann Oncol. 2000;11(Suppl 3):7-11.
133. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus Statement on postmastectomy radiation therapy [review]. Int J Radiat Oncol Biol Phys. 1999;44:989-990.
134. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539-1569.
135. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2): S69-S74.
136. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol. 1997;15:207-215.
137. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, Vijver van de HJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation to outcome. Br J Cancer. 2003;88:406-412.